Hims plans biomarker testing with peptide membership as longevity companies seek proof for coverage

Hims described plans to bundle tests with its peptide membership. Fountain Life and Viome explained why broader adoption depends on evidence and payment.

Author
HDM Staff
Save
Share
Four panelists seated on the HLTH USA Main Stage.
The longevity panel on the HLTH USA Main Stage. Photo credit: HLTH USA 2026.

    Hims & Hers plans to include biomarker testing in its upcoming peptide membership, Dr. Anant Vinjamoori, chief medical officer for Hims, said during a Nov. 16 Main Stage panel in Las Vegas. The consumer program would combine testing with access to treatment. Vinjamoori said Hims expects to draw on tests available elsewhere in the industry. He did not say which measurements the program would use, how often people would be tested or what would change after a particular result.

    Heather Landi, executive editor of Fierce Healthcare, moderated the discussion with Vinjamoori, Fountain Life chief medical officer Dr. Dawn Mussallem and Viome founder and CEO Naveen Jain. Landi asked how longevity services might reach people beyond those who can pay for them today. The panelists described three routes. Hims is betting on consumers purchasing the service, Fountain Life wants evidence that would interest insurers and employers, and Viome sees a need for healthcare organizations to be able to bill for a test before they can adopt it.

    What the Hims membership would include

    Vinjamoori said the offering was “launching very soon.” He described “biomarker testing” as part of a membership intended to give the company a more individualized view of its customers. Hims & Hers had previously previewed its Peptides+ specialty. The additional detail from the stage was the plan to include testing in the membership and to use tests from elsewhere in the industry. There was no discussion of a validated threshold that would determine when a member would be offered a particular treatment.

    That distinction matters to a company selling testing and treatment together. A test can show a difference between two measurements, but a care team still needs to know whether that difference is large enough to matter and what it should do in response. A repeat test can also reveal variation that has little to do with whether someone’s health has improved. The session supplied a product plan and left those questions of clinical performance open.

    Vinjamoori acknowledged that the company has less information about some of the products under discussion than it has about FDA-approved drugs. The Food and Drug Administration has separately warned about reports of adverse events associated with intravenous glutathione, alone or in combination with other ingredients. That notice concerns a specific compounded injectable substance, and it does not establish which products or routes Hims will include in the membership. Monitoring a biomarker also cannot establish the safety or effectiveness of a treatment. Those are separate questions that require evidence about the treatment itself. The panel also supplied no evidence that adding the tests to the membership would change clinical decisions compared with the assessments already available to the people it would serve.

    What would persuade an employer or insurer

    Mussallem said Fountain Life follows data prospectively under institutional review board oversight. She said the program has staff including nurse practitioners, coaches and exercise physiologists, in addition to the cost of the tests. That makes the economics different from the price of a screening kit alone. Paying for a test also means accounting for who talks to the member, reviews an unexpected result and helps determine what should happen next.

    The aim is to “collect this data” and show value to employers and insurers, Mussallem said. She offered fewer sick days as one outcome employers might care about. Coverage could follow “if we have proof,” she said. Her description was a case for gathering evidence rather than an announcement that an insurer had agreed to pay. A purchaser looking at sick days would need to know what happens in a comparable group and how the program distinguishes the effect of its services from other reasons people change how often they miss work.

    Mussallem also discussed Fountain Life’s experience finding coronary plaque among people who sought testing, including some who had been judged low risk using other measures. Finding a condition in people who choose to get tested describes the experience of that group. A coverage decision requires a broader question about whether a screening program improves outcomes for the people it would reach, including those who have to undergo further evaluation after an unexpected result.

    The broader panel also made room for prevention outside a membership. Mussallem described work in Jacksonville, Florida, involving community gardens, safer sidewalks and access to healthier foods. Those efforts illustrate a different route to improving health. They change what is available in a community rather than asking each person to start by buying a test. They also show that an employer or insurer focused on prevention has choices about where to put its money.

    A test also needs a way into the healthcare system

    Jain argued that “you can’t improve something unless you measure it.” His company sells tests and uses the results to make recommendations. He recounted showing predictive work to a large healthcare system and hearing that there was “no billing code for it.” That was his account of one conversation. It points to a practical issue for companies asking a health system to adopt a test. The health system needs a reason to use it and a way to pay for collecting the result, reviewing it and acting on it.

    A billing code can address one piece of that problem. It does not show whether using the test is beneficial or whether a clinician can act on a result. Conversely, an employer deciding whether to pay for a program could ask about a whole service rather than the reimbursement for a single test. Those routes to adoption put different demands on companies. One has to explain where the test fits in care. The other has to make a case that the service, taken as a whole, improves something the buyer can measure.

    Vinjamoori expects consumers to keep driving demand in the near term. Mussallem described a path from prospectively collected evidence to coverage decisions. Jain described a barrier inside the existing payment system. The immediate announcement was Hims’s plan to bring testing into a membership people can purchase. Landi’s financing question exposed what the three companies still have to establish if the services are to reach a wider population. The evidence has to connect what is measured to decisions clinicians and patients can make and to outcomes a purchaser can evaluate.